Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • M. Luisa Iruela-ArispeEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101915


Historical Background

Vascular Endothelial Growth Factor (VEGF) was first identified as a molecule secreted by tumor cells that promoted breakdown of endothelial barrier and induced vascular permeability (Senger et al. 1983). Subsequent purification of the protein and amino acid sequence revealed that this molecule was identical to a cDNA that coded for a protein with mitogenic properties when applied to endothelial cells (Leung et al. 1989; Senger et al. 1990). It became clear that both molecules were identical with functional attributes that included induction of proliferation, migration, and disruption of barrier function on endothelial cells (Connolly et al. 1989; Dvorak 2006). It was quickly determined that VEGF exerted its effects through binding to two cell-surface receptor tyrosine kinases expressed by endothelial cells. Therefore,...

This is a preview of subscription content, log in to check access.


  1. Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Chakravarthy R. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer. 2012;79:307–11.CrossRefPubMedGoogle Scholar
  2. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290:H547–59.CrossRefPubMedGoogle Scholar
  3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Cao Y, Arbiser J, De Amato RJ, De Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011;3:114rv3.PubMedGoogle Scholar
  5. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declrecq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435–9.PubMedCrossRefGoogle Scholar
  6. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470–8.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res. 2006;312:522–6.CrossRefPubMedGoogle Scholar
  8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.CrossRefPubMedGoogle Scholar
  9. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–42.CrossRefGoogle Scholar
  10. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–86.CrossRefGoogle Scholar
  11. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007;130:691–703.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169:681–91.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.CrossRefGoogle Scholar
  14. Rafii S, Butler JM, Ding BS. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529:316–25.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Senger DR, Connolly DT, Van De Water L, Feder J, Dvorak HF. Purification and NH-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774–8.PubMedGoogle Scholar
  16. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5.CrossRefPubMedGoogle Scholar
  17. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signaling. Nat Rev Mol Cell Biol. 2016;17:611–25.CrossRefPubMedGoogle Scholar
  18. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs. 2010;2:165–75.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Zheng W, Aspelund A, Alitalo K. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest. 2014;124:878–87.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Molecular, Cell and Developmental BiologyMolecular Biology Institute – UCLALos AngelesUSA